TOP TEN perturbations for Q05901 (Homo sapiens)

Organism: Homo sapiens
Gene: Q05901
Selected probe(set): 207859_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q05901 (207859_s_at) across 5880 perturbations tested by GENEVESTIGATOR:

Parkinson's disease study 26 (BRAAK V-VI) / normal substantia nigra tissue

Relative Expression (log2-ratio):-1.797781
Number of Samples:7 / 8
Experimental Parkinson's disease study 26 (BRAAK V-VI)
Substantia nigra biopsies derived postmortem from subject with sporadic Parkinson's disease BRAAK stage V-VI, age of onset > 45 years. Parkinson disease duration 17.7 years ± 6.7. The subjects had no history of cancer or concomitant disease of CNS. Mean age at death 78.5 (±8.5). Further neuropathological characteristics: median neurofibrillary tangle score (NFT) 1 (range 0-2); median amyloid-beta score A (range 0-C); mean neuronal cell density 2575 (± 530).
Control normal substantia nigra tissue
Substantia nigra biopsies derived postmortem from neurologically healthy age-matched subjects. Age at death 75.5 (±7.6). Neuropathological characteristics: BRAAK stage 0; median neurofibrillary tangle score (NFT) 1 (range 0-2); median amyloid-beta score 0 (range 0-B); mean neuronal cell density 6659 (± 960).

diabetes type 1 study 5 (recent) / diabetes type 1 study 5 (clinical)

Relative Expression (log2-ratio):-1.0809317
Number of Samples:3 / 3
Experimental diabetes type 1 study 5 (recent)
Pancreas tissue obtained post-mortem from patients with recent onset of type 1 diabetes.
Control diabetes type 1 study 5 (clinical)
Pancreas tissue obtained post-mortem from patients with clinical onset of type 1 diabetes.

Parkinson's disease study 10 / normal postmortem substantia nigra tissue

Relative Expression (log2-ratio):-1.0553255
Number of Samples:16 / 9
Experimental Parkinson's disease study 10
Substantia nigra tissue from postmortem brain of Parkinson's disease (PD) patients.
Control normal postmortem substantia nigra tissue
Substantia nigra tissue from postmortem brain of normal controls.

pancreatic cancer study 1 / uninvolved pancreas tissue

Relative Expression (log2-ratio):-0.918911
Number of Samples:36 / 15
Experimental pancreatic cancer study 1
Tumor sample obtained from patients with pancreatic cancer.
Control uninvolved pancreas tissue
Normal pancreas sample obtained from patients with pancreatic cancer.

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-0.81316423
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

T-cell isolation study 11 / T-cell isolation study 6

Relative Expression (log2-ratio):0.79177094
Number of Samples:2 / 2
Experimental T-cell isolation study 11
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.
Control T-cell isolation study 6
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)

Relative Expression (log2-ratio):-0.77962923
Number of Samples:3 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted).

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-0.7724042
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):0.75372505
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-0.7491956
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.